Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.18 EUR
Change Today +0.015 / 0.69%
Volume 0.0
EH3A On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 3:43 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

amarin corp plc -adr (EH3A) Snapshot

Open
€2.13
Previous Close
€2.16
Day High
€2.18
Day Low
€2.06
52 Week High
03/16/15 - €3.35
52 Week Low
11/11/14 - €0.62
Market Cap
383.5M
Average Volume 10 Days
1.8K
EPS TTM
--
Shares Outstanding
176.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARIN CORP PLC -ADR (EH3A)

amarin corp plc -adr (EH3A) Related Businessweek News

No Related Businessweek News Found

amarin corp plc -adr (EH3A) Details

Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product includes Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

201 Employees
Last Reported Date: 03/3/15
Founded in 1989

amarin corp plc -adr (EH3A) Top Compensated Officers

Chief Executive Officer, President, Assistant...
Total Annual Compensation: $395.2K
Senior Vice President and President of Resear...
Total Annual Compensation: $384.3K
Chief Compliance Officer, Senior Vice Preside...
Total Annual Compensation: $358.0K
Compensation as of Fiscal Year 2013.

amarin corp plc -adr (EH3A) Key Developments

Amarin Corporation plc Announces Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Amarin Corporation plc announced audited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net product revenues of $16.480 million against $10.106 million a year ago. These increases in product revenues are primarily attributable to increases both in new and recurring prescriptions of Vascepa. Operating loss was $20.200 million against $32.888 million a year ago. Loss from operations before taxes was $23.779 million against $13.778 million a year ago. Net loss was $19.657 million against $15.411 million a year ago. Diluted was $0.11 against $0.27 a year ago. Adjusted net loss for EPS-non GAAP was $18.510 million or $0.11 per basic and diluted share against $44.119 million or $0.26 per basic and diluted share a year ago. For the year, the company reported net product revenues of $54.202 million against $26.351 million a year ago. These increases in product revenues are primarily attributable to increases both in new and recurring prescriptions of Vascepa. Operating loss was $95.955 million against $182.106 million a year ago. Loss from operations before taxes was $59.201 million against $169.421 million a year ago. Net loss was $56.364 million against $166.227 million a year ago. Diluted was $0.36 against $1.28 a year ago. Adjusted net loss for EPS-non GAAP was $99.351 million or $0.57 per basic and diluted share against $202.955 million or $1.26 per basic and diluted share a year ago. Net cash used in operating activities in the year ended December 31, 2014 included approximately $44.3 million in sales and marketing related expenses and approximately $30.5 million of costs incurred through the company's contracted clinical research organization and for clinical trial materials in support of the REDUCE-IT cardiovascular outcomes study. The improvement in net cash used in operating activities from operations to $72.3 million in the year ended December 31, 2014 compared to $190.3 million in the same period in 2013 reflects the company's focus on cash preservation and efficient spend targeting to maximize Vascepa revenues and minimize cash burn. It is anticipated that the company will experience fluctuations in quarterly net cash used in operating activities in the future.

Amarin and Eddingpharm Enter into an Agreement to Develop and Commercialize Vascepa

Amarin and Eddingpharm have entered an agreement to develop and commercialise Vascepa (icosapent ethyl), a highly concentrated formulation of omega-3 fatty acid found in fish oil, in mainland China, Hong Kong, Macau, and Taiwan. Under the agreement, Eddingpharm will manage development and commercialisation activities, while Amarin will provide assistance and supply the treatment. Eddingpharm will also pay Amarin upfront and milestone payments of up to USD 169 million, which includes a non-refundable USD 15-million upfront payment, and milestone payments of up to an additional USD 154 million. Eddingpharm will also pay Amarin double-digit percentage royalties on net sales of Vascepa.

Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa (Icosapent Ethyl) in China

Amarin Corporation plc and Eddingpharm, announced an exclusive agreement for Eddingpharm to develop and commercialize Vascepa (icosapent ethyl) in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan for uses that are currently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa. Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EH3A:GR €2.18 EUR +0.015

EH3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $60.94 USD -0.03
BioMarin Pharmaceutical Inc $120.95 USD -3.67
Enzymotec Ltd $7.08 USD -0.12
Jazz Pharmaceuticals PLC $171.03 USD -1.76
Regeneron Pharmaceuticals Inc $441.18 USD -10.30
View Industry Companies
 

Industry Analysis

EH3A

Industry Average

Valuation EH3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARIN CORP PLC -ADR, please visit www.amarincorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.